BioSpace News Archive

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will participate in the following investor conferences in September:

Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount Sinai, in New York, NY, for the use of allogenic hematopoietic stem cell expansion and transplantation technology in blood and bone marrow cancer.

Galectin Therapeutics Inc. (NASDAQ: GALT) announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, including liver cirrhosis.

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today showcased new data at the Exosome Based Therapeutic Development Summit 5th Annual Meeting held September 5-7, 2023 in Boston.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.

Celularity Inc. today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences.

Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France.

Lumos Pharma, Inc. announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th.

Syros Pharmaceuticals today announced the grant of restricted stock unit (RSU) awards for an aggregate of 20,650 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros.